But since the "Barbie" movie released in July, there has been an uptick in demand for use as a cosmetic procedure. Meanwhile, Revance and Evolus Inc (EOLS.O), which make similar toxins under the brand Daxxify and Jeuveau, respectively, told Reuters that though "Barbie Botox" has picked up in recent months, they do not see the trend significantly boosting sales. However, the doctors said they were concerned about a rise in use among younger women - and six doctors warned that procedures by underqualified staff at some medispas raised the risk of complications. Doctors also stressed the risk with administration by people who may not be properly qualified, especially at medispas where there is little oversight. "The science isn't quite there yet, in order to support the clinical profile of it," said Evolus CEO David Moatazedi.

---

Persons: Margot Robbie, BarbieBotox, that's, Barbie, Dustin Sjuts, Scot Glasberg, Revance, Shilpi Kheterpal, Kheterpal, Doctors, Melissa Levoska, David Moatazedi, Leroy Leo, Sriraj Organizations: Therapeutics, Reuters, Plastic Surgery Foundation, U.S . Food, Drug Administration, Evolus Inc, AbbVie Inc, Cleveland Clinic, Icahn School of Medicine, Thomson Locations: New York, U.S, medispas, Mount Sinai, Bengaluru